Risk of seizure recurrence in people with single seizures and early epilepsy - Model development and external validation
- PMID: 34852983
- PMCID: PMC8776562
- DOI: 10.1016/j.seizure.2021.11.007
Risk of seizure recurrence in people with single seizures and early epilepsy - Model development and external validation
Abstract
Purpose: Following a single seizure, or recent epilepsy diagnosis, it is difficult to balance risk of medication side effects with the potential to prevent seizure recurrence. A prediction model was developed and validated enabling risk stratification which in turn informs treatment decisions and individualises counselling.
Methods: Data from a randomised controlled trial was used to develop a prediction model for risk of seizure recurrence following a first seizure or diagnosis of epilepsy. Time-to-event data was modelled via Cox's proportional hazards regression. Model validity was assessed via discrimination and calibration using the original dataset and also using three external datasets - National General Practice Survey of Epilepsy (NGPSE), Western Australian first seizure database (WA) and FIRST (Italian dataset of people with first tonic-clonic seizures).
Results: People with neurological deficit, focal seizures, abnormal EEG, not indicated for CT/MRI scan, or not immediately treated have a significantly higher risk of seizure recurrence. Discrimination was fair and consistent across the datasets (c-statistics: 0.555 (NGPSE); 0.558 (WA); 0.597 (FIRST)). Calibration plots showed good agreement between observed and predicted probabilities in NGPSE at one and three years. Plots for WA and FIRST showed poorer agreement with the model underpredicting risk in WA, and over-predicting in FIRST. This was resolved following model recalibration.
Conclusion: The model performs well in independent data especially when recalibrated. It should now be used in clinical practice as it can improve the lives of people with single seizures and early epilepsy by enabling targeted treatment choices and more informed patient counselling.
Keywords: Independent data; Newly diagnosed; Prognosis; Risk assessment.
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Figures



Similar articles
-
Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review.Cochrane Database Syst Rev. 2019 Jun 24;6(6):CD012065. doi: 10.1002/14651858.CD012065.pub3. Cochrane Database Syst Rev. 2019. PMID: 31233229 Free PMC article.
-
Predicting seizures in pregnant women with epilepsy: Development and external validation of a prognostic model.PLoS Med. 2019 May 13;16(5):e1002802. doi: 10.1371/journal.pmed.1002802. eCollection 2019 May. PLoS Med. 2019. PMID: 31083654 Free PMC article.
-
Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review.Cochrane Database Syst Rev. 2018 Oct 24;10(10):CD001904. doi: 10.1002/14651858.CD001904.pub4. Cochrane Database Syst Rev. 2018. PMID: 30353945 Free PMC article.
-
Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review.Cochrane Database Syst Rev. 2019 Jul 18;7(7):CD001911. doi: 10.1002/14651858.CD001911.pub4. Cochrane Database Syst Rev. 2019. PMID: 31318037 Free PMC article.
-
Predictive models for starting antiseizure medication withdrawal following epilepsy surgery in adults.Brain. 2023 Jun 1;146(6):2389-2398. doi: 10.1093/brain/awac437. Brain. 2023. PMID: 36415957
Cited by
-
Epilepsy and nicotine use: Exploring disparities in ENDS and cigarette use among US adults with epilepsy.Epilepsy Behav. 2025 Jan;162:110177. doi: 10.1016/j.yebeh.2024.110177. Epub 2024 Nov 29. Epilepsy Behav. 2025. PMID: 39612631
-
Predicting seizure recurrence after an initial seizure-like episode from routine clinical notes using large language models: a retrospective cohort study.Lancet Digit Health. 2023 Dec;5(12):e882-e894. doi: 10.1016/S2589-7500(23)00179-6. Lancet Digit Health. 2023. PMID: 38000873 Free PMC article.
-
Polygenic risk scores as a marker for epilepsy risk across lifetime and after unspecified seizure events.medRxiv [Preprint]. 2023 Nov 27:2023.11.27.23297542. doi: 10.1101/2023.11.27.23297542. medRxiv. 2023. Update in: Nat Commun. 2024 Jul 25;15(1):6277. doi: 10.1038/s41467-024-50295-z. PMID: 38076931 Free PMC article. Updated. Preprint.
-
Polygenic risk scores as a marker for epilepsy risk across lifetime and after unspecified seizure events.Nat Commun. 2024 Jul 25;15(1):6277. doi: 10.1038/s41467-024-50295-z. Nat Commun. 2024. PMID: 39054313 Free PMC article.
References
-
- Hauser W.A., Beghi E. First seizure definitions and worldwide incidence and mortality. Epilepsia. 2008;49(s1):8–12. - PubMed
-
- Berg A.T., Shinnar S. The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology. 1991;41(7):965–972. - PubMed
-
- Marson A., et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet. 2005;365(9476):2007–2013. - PubMed
-
- Jacoby A., et al. Quality-of-life outcomes of initiating treatment with standard and newer antiepileptic drugs in adults with new-onset epilepsy: findings from the SANAD trial. Epilepsia. 2015;56(3):460–472. - PubMed